Oral Biolife was founded in 2022 to offer PiezoGEL, a piezoelectric hydrogel to treat periodontal disease.
As CEO, Mr. Breitenbach will oversee operations and research and development as well as the launch of PiezoGEL, according to a June 5 news release.
Mr. Breitenbach has more than 25 years of experience serving in executive roles in the pharmaceutical, biopharmaceutical and biotech industries.
